Albert B. Sabin Vaccine Institute
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Albert B. Sabin Vaccine Institute sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
Albert B. Sabin Vaccine Institute: 4 sponsored US clinical trials, none currently recruiting.
Albert B. Sabin Vaccine Institute sponsors 4 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 2 completed. 0 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Marburg Virus Disease, with 1 trials.
Upper-quartile sponsor footprint
Albert B. Sabin Vaccine Institute sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
4 total, page 1 of 1
A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Sudan Ebolavirus Vaccine in Healthy Adults
NCT06803342
A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Marburg Virus Vaccine in Healthy Adults
NCT06620003
Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults
NCT04723602
Development of a Skin Test for the Na-ASP-2 Hookworm Antigen
NCT00603889
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 2 |
Therapeutic Areas
How the Albert B. Sabin Vaccine Institute early-phase archive is shaped
4 indexed studies, none listed as recruiting (0% open); 2 completed (50%).
Phase mix: 0 late (III/IV) vs 3 early (I/II) (early-phase heavy).
Top condition: Marburg Virus Disease (1 trial), 1 other listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Albert B. Sabin Vaccine Institute: archived-pipeline peers nationwide
Peers matched on 4 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Albert B. Sabin Vaccine Institute sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 archived trials
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Albert B. Sabin Vaccine Institute page
4 registered trials is a research-attention snapshot, not an endorsement of Albert B. Sabin Vaccine Institute or any single study.
- None of Albert B. Sabin Vaccine Institute's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Marburg Virus Disease is the condition Albert B. Sabin Vaccine Institute studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Marburg Virus Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Albert B. Sabin Vaccine Institute pipeline card: 4 registered trials from official public datasets.Report a data error.